Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study.
A multicentre, controlled, randomised, open, comparative trial including 839 healthy adult volunteers was carried out in order to compare the immunogenicity and reactogenicity of two vaccines against hepatitis A virus (HAV) during primary immunization and after booster injection. The first vaccine was produced by Pasteur Mérieux (PM), and the second vaccine by Smith-Kline Beecham (SKB). The vaccination schedule consisted of 2 doses (months 0, 6) for PM and 3 doses (months 0, 1, and 6) for SKB. Two weeks after the first dose, the seroconversion rates among initially HAV seronegative subjects (n = 608) were 93.4% and 76.1% for the PM and SKB vaccines, respectively, the corresponding geometric mean titres (GMTs) were 59.0 mIU/ml versus 30.8 mlU/ml (modified RIA HAVAB assay, Abbott Laboratories). Two months after the beginning of immunization (one dose versus two doses) the GMTs were 138.4 and 161.6 mlU/ml, respectively. At month 7, the seroconversion rates were 100% for both vaccines, and the GMTs were 4,189 and 3,163 mlU/ml, respectively. After the first dose of vaccine, 24.6% and 19.6% of the PM and SKB vaccines reported local reactions. The rates for systemic reactions were 27.2% and 25.0%, respectively. Lower rates for local and systemic reactions were seen after booster injections and statistical differences were not observed between the two vaccines. The study also demonstrated that vaccination was as well tolerated in subjects with anti-HAV antibodies as in HAV seronegative subjects. Logistic regression analysis revealed a significant vaccine effect on seroconversion rates only at week 2 (P < 10(-4). The same conclusions were drawn from the analysis of GMT by multivariate regression.(ABSTRACT TRUNCATED AT 250 WORDS)
Goilav
C
C
Microbiology Department AZ-VUB, Brussels, Belgium.
Zuckerman
J
J
Lafrenz
M
M
Vidor
E
E
Lauwers
S
S
Ratheau
C
C
Benichou
G
G
Zuckerman
A
A
D000293:Adolescent; D000328:Adult; D003257:Consumer Product Safety; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D006507:Hepatovirus / Q000276:immunology*; D006801:Humans; D007125:Immunogenetics; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines